Glucocorticoid_NN
receptors_NNS
in_IN
systemic_JJ
lupus_NN
erythematosus_NN
._.

Glucocorticosteroids_NNS
remain_VBP
the_DT
major_JJ
treatment_NN
modality_NN
for_IN
systemic_JJ
lupus_NN
erythematosus_NN
-LRB-_-LRB-
SLE_NN
-RRB-_-RRB-
,_,
but_CC
their_PRP$
mechanism_NN
of_IN
action_NN
is_VBZ
unclear_JJ
._.

Over_IN
the_DT
past_JJ
decade_NN
it_PRP
has_VBZ
become_VBN
clear_JJ
that_IN
glucocorticosteroid_NN
receptors_NNS
play_VBP
a_DT
significant_JJ
role_NN
in_IN
the_DT
mechanism_NN
of_IN
glucocorticosteroid_NN
action_NN
._.

We_PRP
studied_VBD
glucocorticosteroid_NN
receptor_NN
density_NN
and_CC
affinity_NN
on_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
by_IN
the_DT
glucocorticosteroid_NN
binding_NN
assay_NN
in_IN
33_CD
patients_NNS
with_IN
SLE_NN
who_WP
had_VBD
taken_VBN
no_DT
glucocorticosteroid_NN
for_IN
the_DT
previous_JJ
6_CD
months_NNS
and_CC
in_IN
32_CD
healthy_JJ
controls_NNS
._.

Patients_NNS
'_POS
disease_NN
activity_NN
was_VBD
measured_VBN
by_IN
the_DT
SLE_NNP
Disease_NNP
Activity_NNP
Index_NNP
-LRB-_-LRB-
SLEDAI_NN
-RRB-_-RRB-
._.

Glucocorticosteroid_NN
receptors_NNS
on_IN
leukocytes_NNS
of_IN
patients_NNS
with_IN
SLE_NN
were_VBD
significantly_RB
higher_JJR
than_IN
in_IN
healthy_JJ
controls_NNS
-LRB-_-LRB-
4419_JJ
+_CC
\/_JJ
-_CC
306_CD
vs_CC
3369_CD
+_NNP
\/_CD
-_:
196_CD
,_,
p_NN
less_JJR
than_IN
0.005_CD
-RRB-_-RRB-
._.

The_DT
binding_VBG
affinity_NN
was_VBD
not_RB
different_JJ
between_IN
patients_NNS
and_CC
controls_NNS
._.

There_EX
was_VBD
no_DT
correlation_NN
between_IN
glucocorticosteroid_NN
receptor_NN
number_NN
and_CC
SLE_NN
disease_NN
activity_NN
._.

